Dutch vaccine development company Mucosis BV has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs.
Mucosis will use this loan for the clinical development of its lead product FluGEM, an influenza vaccine administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM clinical development programme is concluded successfully.
“This non-dilutive funding underlines the progress we have made so far and, even more importantly, strengthens our financial capabilities going forward. It will enable us to generate proof of efficacy with FluGEM in man,” said Govert Schouten, CEO.